Chen Wang-Yang, Zhao Xiao-Juan, Yu Zhi-Fu, Hu Fu-Lan, Liu Yu-Peng, Cui Bin-Bin, Dong Xin-Shu, Zhao Ya-Shuang
Department of Epidemiology, Public Health College, Harbin Medical University Harbin, Heilongjiang 150081, P. R. China.
Department of Abdominal Surgery, The Tumor Hospital of Harbin Medical University Harbin, Heilongjiang Province, P. R. China.
Int J Clin Exp Pathol. 2015 Jun 1;8(6):7092-101. eCollection 2015.
Circulating microRNAs (miRNAs) were recognized to be potential non-invasive biomarkers for colorectal cancer (CRC) detection and prediction. Meanwhile, the association of the expression of plasma miRNAs with the risk of CRC patients has rarely been analyzed. Therefore, we conducted this study to evaluate the value of plasma miRNAs for CRC diagnosis and risk estimation. Fasting blood samples from 100 CRC patients and 79 cancer-free controls were collected. Plasma miR-106a, miR-20a, miR-27b, miR-92a and miR-29a levels were detected by RT-qPCR. Sensitivity and specificity were employed to evaluate the diagnostic value of miRNAs for CRC. Univariate and multivariate logistic regression were employed to analyze the association between miRNAs expression and CRC risk. As results, miR-106a and miR-20a were elevated in the patients with CRC. The sensitivity of miR-106a was 74.00% and the specificity was 44.40%, while the cutoff value was 2.03. As for miR-20a, the sensitivity was 46.00% and specificity was 73.42% when employed 2.44 as cutoff value. High expression of plasma miR-106a increased CRC risk by 1.80 -fold. Plasma miR-106a and miR-20a may as noninvasive biomarkers for detecting the CRC. High expression of miR-106a associated with CRC risk.
循环微小RNA(miRNA)被认为是用于结直肠癌(CRC)检测和预测的潜在非侵入性生物标志物。同时,血浆miRNA表达与CRC患者风险之间的关联很少被分析。因此,我们开展了这项研究以评估血浆miRNA在CRC诊断和风险评估中的价值。收集了100例CRC患者和79例无癌对照的空腹血样。通过RT-qPCR检测血浆miR-106a、miR-20a、miR-27b、miR-92a和miR-29a水平。采用敏感性和特异性评估miRNA对CRC的诊断价值。采用单因素和多因素逻辑回归分析miRNA表达与CRC风险之间的关联。结果显示,CRC患者中miR-106a和miR-20a升高。miR-106a的敏感性为74.00%,特异性为44.40%,临界值为2.03。对于miR-20a,以2.44为临界值时,敏感性为46.00%,特异性为73.42%。血浆miR-106a高表达使CRC风险增加1.80倍。血浆miR-106a和miR-20a可能作为检测CRC的非侵入性生物标志物。miR-106a高表达与CRC风险相关。